Gastric resident electronics, devices, systems, and related methods are generally provided. Some embodiments comprise administering (e.g., orally) an (electronic) resident structure to a subject (e.g., a patient) such that the (electronic) resident structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before exiting said location internal to the subject. In some embodiments, the resident structure is a gastric resident electronic. That is to say, in some embodiments, the resident structure is configured for relatively long gastric residence and comprises an electronic component. In some embodiments, the structures and components described herein may comprise one or more components configured for the delivery of an active substance(s) (e.g., a pharmaceutical agent) to the subject. In some embodiments, the device has a modular design, combining an electronic component(s) with materials configured for controlled and/or tunable degradation/dissolution to determine the time at which (gastric) residence is lost and the device exits the location internal to the subject. For example, in some embodiments, the resident structure comprises an electronic component and one or more additional components associated with the electronic component such that the resident structure is configured to be retained at a location internal to a subject for greater than or equal to 24 hours.

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

A pharmaceutical composition may be used in administering oxygen to a subject. The pharmaceutical composition may contain a perfluorocarbon dissolving oxygen therein. Further, a pharmaceutical composition may be used in decreasing the blood carbon dioxide partial pressure of a subject, and the pharmaceutical composition may contain a perfluorocarbon. Such a composition may be suitable for administered oral administration, nasogastric administration, trans-fistula gastric administration, or administration into a large intestine.

Implementations of a delivery device and method are disclosed. One implementation is a delivery device comprising a flow chamber with an inlet port for receiving a fluid flow in the flow chamber, and an outlet port for exiting a material from the flow chamber. The flow chamber may include a formation portion in which a suspension of the material is formed, and a collection portion that directs the suspension toward and/or into the outlet port. An amount of the material may collect in the collection portion adjacent the outlet port. The device may further comprise an insertion port for permitting insertion of the material in the flow chamber, and/or a pusher operable to move the amount of material through the outlet port. Related devices and methods also are disclosed.

Herein disclosed are nasal inserts for treatment and/or management of various different ailments. Easy modification of the insert allows for treatment of various ailments that can readily be treated via the nose. The insert can direct air into or out of the nasal cavity and/or deliver medicinal substances and/or non-medicinal substances to the appropriate regions, thereby providing the appropriate therapeutic effect, depending on the ailment being treated.

The present invention relates to a microcontainer microstructure including a microcontainer film structure having a sharp tip portion and a method of manufacturing the same.

Methods and apparatus are disclosed for customizing an elution rate of a stent. The stent includes a hollow strut that forms the stent, the hollow strut defining a lumenal space, a drug formulation disposed within the lumenal space of the hollow strut, and at least one side port for eluting the drug formulation in vivo. When the stent is in the radially expanded configuration the hollow strut is deformable from a first configuration that has a first elution rate for the drug formulation to a second configuration that has a second elution rate for the drug formulation. The second elution rate is faster than the first elution rate. The hollow strut deforms from the first configuration to the second configuration upon application of an applied pressure above a predetermined threshold.

A therapeutic delivery device that provides a controlled release of high doses of a therapeutic agent in a local area, sustains the high dose controlled release with a percutaneous port for refilling the device, and is versatile for use with multiple types of therapeutic agents and/or implant systems. A rate determining/controlled release membrane is used to decrease the molecular mobility of the therapeutic compounds thereby controlling the therapeutic release profile. The therapeutic delivery device includes a body defining an internal reservoir for receiving a therapeutic agent and including a first membrane for providing a controlled release of the therapeutic agent to the surgical site, a port in fluid communication with the reservoir, a sleeve configured to encapsulate the body, and a rigid housing configured to support the body and a portion of the sleeve, the rigid housing configured to release the body and the sleeve after the body and the sleeve are anchored position relative to the surgical site.

Provided herein is technology relating to materials having microscale and/or nanoscale features and particularly, but not exclusively, to porous materials comprising microscale features, methods for producing porous materials comprising microscale features, drug delivery vehicles, and related kits, systems, and uses.

A single or multi layered device (hereinafter alternately referred to as a “capsule”) of non-digestible material encapsulating an ingestible drug solution capable of slow solution release of stable solubilized drugs in water, saline, a buffer or lipophilic acceptable carriers. Methods for preparing the same and for safe, nearly constant dispensing of drugs following capsule swallowing. A safe, controlled flow release mechanism for the capsule's drug to the gastric system is disclosed.